CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3

Despite significant progress in cancer therapy over the last decades, ovarian cancer remains the most lethal gynecologic malignancy worldwide with the five-year overall survival rate less than 30% due to frequent disease recurrence and chemoresistance. CD44 is a non-kinase transmembrane receptor tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Martincuks, Antons, Li, Pei-Chuan, Zhao, Qianqian, Zhang, Chunyan, Li, Yi-Jia, Yu, Hua, Rodriguez-Rodriguez, Lorna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736609/
https://www.ncbi.nlm.nih.gov/pubmed/33335857
http://dx.doi.org/10.3389/fonc.2020.589601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7736609/
https://www.ncbi.nlm.nih.gov/pubmed/33335857
http://dx.doi.org/10.3389/fonc.2020.589601

Ejemplares similares